RSS Feeds
Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease
- Nanette K. Wenger, MD;
- Sandra J. Lewis, MD;
- David M. Herrington, MD;
- Vera Bittner, MD;
- Francine K. Welty, MD, PhD; and
- for the Treating to New Targets Study Steering Committee and Investigators
- From Emory University School of Medicine, Atlanta, Georgia; Northwest Cardiovascular Institute, Portland, Oregon; Wake Forest University School of Medicine, Winston–Salem, North Carolina; University of Alabama at Birmingham, Birmingham, Alabama; and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
-
Figure 1. Mean low-density lipoprotein (LDL) cholesterol levels (top) and mean triglyceride levels (bottom) among patients 65 years of age or older.To convert LDL cholesterol values to mg/dL, divide by 0.02586. To convert triglyceride values to mg/dL, divide by 0.01129.
-
Figure 2. Cumulative incidence of a major cardiovascular event (top) and fatal or nonfatal stroke (bottom).The hazard ratio for a major cardiovascular event is 0.81 (95% CI, 0.67 to 0.98) (P = 0.03) among patients 65 years of age or older and 0.76 (CI, 0.64 to 0.90) (P = 0.001) among patients younger than 65 years of age. The hazard ratio for fatal or nonfatal stroke is 0.79 (CI, 0.57 to 1.09) (P = 0.158) and 0.70 (CI, 0.49 to 1.00) (P = 0.048), respectively.
-
Figure 3. Hazard ratios and heterogeneity tests for primary and secondary outcomes among patients 65 years of age or older (solid circles) and those younger than 65 years of age (open circles).CA = cardiac arrest; CHD = coronary heart disease; CHF = congestive heart failure; CV = cardiovascular; MI = myocardial infarction; PAD = peripheral artery disease; PR = procedure-related. *P value for heterogeneity (patients ≥65 years vs. patients <65 years).
Related Clinical Content
